ArticleJournal of oral and maxillofacial pathology : JOMFP
Evaluation of immuno-expression of galectin-3 in oral submucous fibrosis and healthy oral mucosa.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibrotic-Angiogenic Signaling Networks in Oral Submucous Fibrosis: Pathobiology and Therapeutic Targeting.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral submucous fibrosis (OSMF) is a potentially premalignant disorder involving oral mucosa presented with 7-13% rate of malignant transformation. Galectin-3 is a chimeric protein presented in the human body which plays an important role in certain physiologic conditions as well as pathologic conditions. Aim: This study aims to assess the impact of Gal-3 on connective tissue remodelling in both normal oral mucosa and OSMF. Materials and Methods: The study sample included 40 individuals who visited the outpatient department of Manubhai Patel Dental College and a private dental clinic. The study samples were divided into two groups: Group I consisted of 20 patients with clinically diagnosed OSMF, and group II consisted of 20 patients with healthy oral mucosa. A punch biopsy was conducted to obtain the mucosal tissue from the appropriate site in each case of group 1. Tissues from healthy buccal mucosa were obtained during minor oral surgical procedures in group 2 cases. The statistical analysis was conducted using the SPSS software, version 20.0, developed by IBM in USA. Results: Based on the examination done according to TFM staging system, most of the cases belonged to stage 3. The majority of the OSMF cases were belonging to the grade III OSMF. Gal-3 immunoreactivity in epithelial cells in OSMF and in normal oral mucosa (NOM) was observed as membranous and cytoplasmic expression. Conclusion: The immuno-expression of Gal-3 was observed to be significantly elevated in the connective tissue near the epithelium in OSMF when compared to NOM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.